Home
Gubra ApS

Gubra ApS Market Share Analysis for November 2025

"Gubra is a CRO and biotech company specialized in high-end preclinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases. The combination of our advanced, high-end models and technologies ensures rapid turnaround time and high quality data."

Health > Biotechnology and Pharmaceuticals

Domaingubra.dk

Year Founded2008

Employees201 - 500

Annual Revenue$25M - $50M

Gubra ApS

Gubra ApS (including company regionals)

gubra.dk

See more website traffic and engagement information

Gubra ApS Revenue up to November 2025 is 25M - 50M

revenue generated by Gubra ApS top domains

Gubra ApS top domains revenue over 3 years

Revenue for Gubra ApS top domains

gubra.dk25M - 50M

See more with Sales Intelligence

Total visits to Gubra ApS's top domains

Understand Gubra ApS market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

gubra.dk24.4K

See more with Sales Intelligence

Avg. visit duration in Gubra ApS's top domains

Analyze Gubra ApS engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

gubra.dk00:01:07

See more with Sales Intelligence

Avg. pageviews on Gubra ApS's top domains

See how Gubra ApS keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

gubra.dk1.69

See more with Sales Intelligence

Gubra ApS top competitors by domain

Top similar sites in November 2025, ranked by their affinity

syneoshealth.comCompany NameSyneos HealthEmployees> 10001HQUnited States, North Carolina, MorrisvilleAnnual revenue> $1BTotal visits194.3KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Gubra ApS

These are the website technologies, by industry, used by Gubra ApS top domains

Widget (6)

Twemoji

Advertising (5)

DoubleClick

Email Services (4)

Sendgrid

Conversion & Analytics (3)

Google Analytics

More Technologies

9

See all

News & Signals from Gubra ApS

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsPila Pharma Ab partnered with Gubra ApS on Sep 1st '25.In September, Pila announced a partnership with Danish research group Gubra to conduct these studies, with results expected in early 2026.

NewsGubra ApS is developing GUB014295.The US pharmaceutical giant AbbVie and danish biotechnology company Gubra, specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, signed a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.

NewsGubra ApS is developing amylin analog for obesity.AbbVie and Gubra strike license deal to develop amylin analog for obesity.